Abhay Kumar is a retired corporate development executive with 30+ years of experience in biotech. Abhay’s focus has been on designing strategies, and business growth by acquisition or licensing of technologies and strategic partnerships. Abhay started his career in 1992 at Hybritech Incorporated, the first biotech company in San Diego, where he identified novel biomarkers for diagnosis of prostate cancer, which are still in clinical use today. Upon acquisition of Hybritech, he continued his work at Beckman Coulter, Inc. in the field of MHC Tetramers and launched multiple products for enumeration of antigen-specific T cells. Abhay was part of strategy and corporate development team at Invitrogen / Life Tech / Thermo Fisher for 14 years and Danaher Corporation (Beckman Coulter Life Sciences and Aldeveon LLC, both Danaher operating companies) for 4 years. During his career, Abhay and team executed 500+ business transactions (ranging from $1M to $500M+), and participated in acquisition and integration of 7 companies. Abhay received his DVM and PhD from G.B. Pant University (India) and Executive MBA from San Diego State University (California). He is a registered patent agent with USPTO. Currently, Abhay advises early-stage companies in the US and India, and support various academic and non-profit organizations in San Diego, California.
